JPH10114665A - Improver for aqueous body fluid and composition for oral administration comprising the same - Google Patents
Improver for aqueous body fluid and composition for oral administration comprising the sameInfo
- Publication number
- JPH10114665A JPH10114665A JP8272724A JP27272496A JPH10114665A JP H10114665 A JPH10114665 A JP H10114665A JP 8272724 A JP8272724 A JP 8272724A JP 27272496 A JP27272496 A JP 27272496A JP H10114665 A JPH10114665 A JP H10114665A
- Authority
- JP
- Japan
- Prior art keywords
- action
- composition
- treatment
- treating
- improving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 210000001124 body fluid Anatomy 0.000 title abstract 4
- 239000010839 body fluid Substances 0.000 title abstract 4
- 230000009471 action Effects 0.000 claims abstract description 54
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 25
- 239000003613 bile acid Substances 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 11
- 235000013305 food Nutrition 0.000 claims abstract description 10
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims abstract description 8
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims abstract description 4
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000004380 Cholic acid Substances 0.000 claims abstract description 3
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims abstract description 3
- 229960002471 cholic acid Drugs 0.000 claims abstract description 3
- 235000019416 cholic acid Nutrition 0.000 claims abstract description 3
- 230000028327 secretion Effects 0.000 claims description 24
- 201000004624 Dermatitis Diseases 0.000 claims description 20
- 230000003779 hair growth Effects 0.000 claims description 16
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 15
- 201000008937 atopic dermatitis Diseases 0.000 claims description 15
- 230000001079 digestive effect Effects 0.000 claims description 10
- 230000001882 diuretic effect Effects 0.000 claims description 10
- 208000007163 Dermatomycoses Diseases 0.000 claims description 9
- 201000004681 Psoriasis Diseases 0.000 claims description 9
- 201000003929 dermatomycosis Diseases 0.000 claims description 9
- 230000019612 pigmentation Effects 0.000 claims description 9
- 206010039796 Seborrhoeic keratosis Diseases 0.000 claims description 8
- 206010048218 Xeroderma Diseases 0.000 claims description 7
- 206010021198 ichthyosis Diseases 0.000 claims description 7
- 230000037380 skin damage Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims 2
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 abstract description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 11
- 230000001225 therapeutic effect Effects 0.000 abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 5
- 210000000056 organ Anatomy 0.000 abstract description 4
- 230000004936 stimulating effect Effects 0.000 abstract description 3
- 230000003248 secreting effect Effects 0.000 abstract description 2
- 206010003645 Atopy Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 31
- 208000010668 atopic eczema Diseases 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 10
- 208000012641 Pigmentation disease Diseases 0.000 description 8
- 208000000260 Warts Diseases 0.000 description 8
- 201000010153 skin papilloma Diseases 0.000 description 8
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- 241000411851 herbal medicine Species 0.000 description 6
- 230000035900 sweating Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- -1 alkali metal salts Chemical class 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 208000006454 hepatitis Diseases 0.000 description 5
- 231100000283 hepatitis Toxicity 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000002500 effect on skin Effects 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000003636 fecal output Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 210000004243 sweat Anatomy 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010048222 Xerosis Diseases 0.000 description 2
- 210000000476 body water Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- DXOCDBGWDZAYRQ-UHFFFAOYSA-N (3alpha,5beta)-3-Hydroxy-7-oxocholan-24 -oic acid Natural products C1CC(O)CC2CC(=O)C3C4CCC(C(CCC(O)=O)C)C4(C)CCC3C21C DXOCDBGWDZAYRQ-UHFFFAOYSA-N 0.000 description 1
- URJQSMIFSMHWSP-VVHBOOHCSA-N 2-[[2-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]acetyl]amino]ethanesulfonic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 URJQSMIFSMHWSP-VVHBOOHCSA-N 0.000 description 1
- OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 description 1
- DXOCDBGWDZAYRQ-AURDAFMXSA-N 7-oxolithocholic acid Chemical compound C1C[C@@H](O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)CC[C@@H]3[C@]21C DXOCDBGWDZAYRQ-AURDAFMXSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 244000080767 Areca catechu Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 238000011735 C3H mouse Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 108010035713 Glycodeoxycholic Acid Proteins 0.000 description 1
- WVULKSPCQVQLCU-UHFFFAOYSA-N Glycodeoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 WVULKSPCQVQLCU-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960002997 dehydrocholic acid Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 229940099347 glycocholic acid Drugs 0.000 description 1
- WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- BHTRKEVKTKCXOH-AYSJQVDDSA-N taurochenodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)C1C2C2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-AYSJQVDDSA-N 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000009538 yokuinin Substances 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、津液作用の改善効
果を有する津液改善剤、及びそれを含有する食品、医薬
等の経口投与用組成物に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an agent for improving tsunami which has an effect of improving the effect of tsunami, and a composition containing the same for oral administration of foods, medicines and the like.
【0002】[0002]
【従来の技術】漢方思想における気、血、水の考え方
は、その薬理作用の捉え方のユニークさと、漢方薬選択
時の合理的な指標であるために、古くより研究されてき
た。これらの内、気、血の意味するものについては、多
くのことが解明されてきた。例えば、血とは酸素、栄養
等エネルギーを中心とする補給・代謝を表すキーワード
であり、気とは生命活動の恒常性機構の活動状況と生命
活動の原動力の状況を表すキーワードであることが知ら
れている。2. Description of the Related Art The concept of qi, blood, and water in Chinese medicine has long been studied because of its uniqueness in understanding its pharmacological action and a rational index for selecting Chinese medicine. Of these, many have been elucidated about the meanings of qi and blood. For example, it is known that blood is a keyword that represents the supply and metabolism mainly of energy such as oxygen and nutrition, and ki is a keyword that represents the status of the homeostasis of life activity and the status of the driving force of life activity. Have been.
【0003】しかし、水(津液)の働きについては老廃
物の代謝・排泄作用のみしか知られておらず、気・血・
水の論理体型において遅れて認識された為、その真の作
用(津液作用)の解明は未完であった。また、津液作用
と現代医学で認識されている種々の薬理作用等との関係
や津液の現代医学における役割などはあまり知られてお
らず、現代医学の分野における津液作用の解明及び津液
作用の改善をもたらす食品や医薬等の開発が望まれてい
た。[0003] However, only the metabolism and excretion of waste products is known for the function of water (tsu liquor).
Since the recognition was delayed in the logical form of water, the elucidation of its true action (Tsukumi action) was incomplete. Also, little is known about the relationship between the pulp action and the various pharmacological actions recognized in modern medicine, and the role of pulp in modern medicine. The development of foods, medicines, etc. that bring about this has been desired.
【0004】[0004]
【発明が解決しようとする課題】本発明はこのような状
況を踏まえてなされたものであり、津液の真の作用を明
らかにし、津液作用を改善しうる物質及びそれを含有す
る食品、医薬等の経口投与用組成物を提供することを課
題とする。DISCLOSURE OF THE INVENTION The present invention has been made in view of such circumstances, and clarifies the true action of tsuju, and can improve the tsuju action, and foods, medicines and the like containing the same. It is an object of the present invention to provide a composition for oral administration.
【0005】[0005]
【課題を解決するための手段】本発明者等は、このよう
な状況に鑑み、津液の真の作用を求めて鋭意研究を重ね
た結果、津液作用が、ある種の物質の働きによって水分
の体外への分泌を司る器官を刺激し、体内水分の体外へ
の分泌を促進させる作用を意味していることを見いだし
た。そして、そのような分泌器官を刺激し津液作用を促
進・改善しうる物質である津液改善剤を見出し、本発明
を完成した。Means for Solving the Problems In view of such a situation, the present inventors have conducted intensive studies in search of the true function of tsuju. It was found that it stimulates the organs responsible for extracorporeal secretion and promotes the secretion of body water out of the body. Then, they found a tsumuco-ameliorating agent, which is a substance capable of stimulating such secretory organs and promoting / improving the action of tsumuju, and completed the present invention.
【0006】すなわち、本発明は、胆汁酸及び/又はそ
の生理的に許容される塩からなる津液改善剤を提供する
ものである。また、本発明は、前記津液改善剤を含有す
る経口投与用組成物を提供するものである。[0006] That is, the present invention provides a tsutsumitsu improving agent comprising bile acid and / or a physiologically acceptable salt thereof. In addition, the present invention provides a composition for oral administration containing the above-mentioned tsukumo-improving agent.
【0007】本発明の津液改善剤とは、水分の体外への
分泌を司る器官を刺激して体内水分の体外への分泌を促
し津液作用を促進・改善する作用、すなわち津液改善作
用を有する物質をいう。本発明者らは、津液作用が真皮
から表皮への水分分泌を促進し表皮に十分な水分を保持
させることによって起こる美肌作用、アトピー性皮膚
炎、湿疹、皮膚真菌症、疣贅、色素沈着症、尋常性乾
癬、老人性乾皮症、老人性角化腫、火傷等の各種皮膚疾
患治療作用、発毛促進作用、発汗促進作用、胃壁、腎
臓、腸管での水分分泌を促進させることによって起こる
消化液分泌促進作用、利尿作用、便通促進作用にかかわ
る作用であることを見出した。[0007] The tsumuco-ameliorating agent of the present invention is a substance having an effect of stimulating an organ responsible for the secretion of water to the outside of the body to promote the secretion of body water to the outside of the body, thereby promoting and improving the effect of the tsuno-solution, that is, a substance having an effect of improving tsuku-solution. Say. The present inventors have proposed a tanning effect that promotes the secretion of water from the dermis to the epidermis and retains sufficient water in the epidermis, a beautiful skin effect, atopic dermatitis, eczema, dermatomycosis, warts, and pigmentation. It is caused by promoting the treatment of various skin diseases such as psoriasis vulgaris, senile xeroderma, senile keratoma, and burns, promoting hair growth, promoting sweating, and promoting water secretion in the stomach wall, kidneys and intestinal tract. It has been found that it is an action related to digestive juice secretion promoting action, diuretic action, and bowel movement promoting action.
【0008】すなわち、漢方生薬の薬効分類を詳細に検
討し、現代医薬分類との対比を行った結果、水(津液)
が関与すると言われている、しゃ下、利水、消導、補陰
と言った薬草群の作用が現代医薬品分類における美肌作
用、アトピー性皮膚炎治療作用、湿疹で代表される皮膚
炎群治療作用、皮膚真菌症治療作用、疣贅治療作用、肝
炎で代表される色素沈着症治療作用、尋常性乾癬治療
症、老人性乾皮症、老人性角化腫治療作用、物理的原因
による皮膚損傷治療作用、発毛促進作用、消化液分泌促
進作用、発汗促進作用、利尿作用、便通促進作用と係わ
りが深いことを見いだした。[0008] That is, the medicinal classification of Chinese herbal medicines was examined in detail, and compared with modern medicine classifications.
It is said that the effects of the herbs such as shampoo, irrigation, conduction and prosthesis are related to beautiful skin effect, atopic dermatitis treatment, and dermatitis group treatment represented by eczema in the modern pharmaceutical classification. , Dermatomycosis treatment, wart treatment, pigmentation such as hepatitis, psoriasis vulgaris, senile xeroderma, senile keratoma treatment, skin damage treatment due to physical causes It has been found that it is closely related to the action, the hair growth promoting action, the digestive juice secretion promoting action, the sweating promoting action, the diuretic action and the bowel movement promoting action.
【0009】この知見をもとに種々の物質について美肌
作用、アトピー性皮膚炎治療作用、発毛促進作用、湿疹
の治療作用、消化液分泌促進作用、発汗促進作用を指標
にスクリーニングを重ねたところ、胆汁酸及び/又はそ
の生理的に許容される塩がこのような作用に優れること
を見いだした。胆汁酸及び/又はその生理的に許容され
る塩が、経皮吸収促進作用、肝機能の改善や免疫機能の
改善作用を有していることは知られているものの、真の
意味での津液改善作用があることは知る余地もなかっ
た。更に、胆汁酸及び/又はその生理的に許容される塩
が美肌作用、アトピー性皮膚炎、湿疹、皮膚真菌症、疣
贅、色素沈着症、尋常性乾癬、老人性乾皮症、老人性角
化腫、火傷等の皮膚疾患治療作用、発毛促進作用、発汗
促進作用、消化液分泌促進作用、利尿作用、便通促進作
用を有することは全く知られていなかった。Based on this finding, screening was carried out on various substances based on the index of skin beautiful action, atopic dermatitis treatment action, hair growth promotion action, eczema treatment action, digestive juice secretion promotion action, sweat promotion action. It has been found that bile acids and / or their physiologically acceptable salts are excellent in such effects. Although it is known that bile acid and / or its physiologically acceptable salt has a percutaneous absorption promoting action, a liver function improving action and an immune function improving action, a true sense of tsuyu There was no room for improvement. Furthermore, bile acids and / or physiologically acceptable salts thereof may be used as a skin beautifier, atopic dermatitis, eczema, dermatomycosis, warts, pigmentation, psoriasis vulgaris, senile xerosis, senile horn It has never been known that it has an action of treating skin diseases such as chemosis and burns, an action of promoting hair growth, an action of promoting sweating, an action of promoting digestive secretion, a diuretic action, and an action of promoting bowel movement.
【0010】[0010]
(1)本発明の津液改善剤 本発明の津液改善剤は、胆汁酸及び/又はその生理的に
許容される塩からなる。胆汁酸としては、コール酸、デ
オキシコール酸、ウルソデオキシコール酸、リトコール
酸、デヒドロコール酸、リトコール酸、グリココール
酸、タウロコール酸、タウログリココール酸、タウロケ
ノデオキシコール酸、タウロデオキシコール酸、グリコ
ケノデオキシコール酸、グリコデオキシコール酸、グリ
コリトコール酸、ケノデオキシコール酸、7−ケトリト
コール酸等が例示でき、これらが何れも使用できる。胆
汁酸の生理的に許容される塩としては、例えば、ナトリ
ウム、カリウム等のアルカリ金属塩、カルシウム、マグ
ネシウム等のアルカリ土類金属塩、アンモニウム塩、ト
リエチルアミンやトリエタノールアミン等の有機アミン
塩、リジンやアルギニン等の塩基性アミノ酸塩等が好ま
しく例示できる。これらの対塩基は1種でも2種以上で
組み合わせて用いても構わない。これらの胆汁酸及び/
又はその生理的に許容される塩はいずれも市販されてお
り、入手可能である。(1) Tsutsumi-improving agent of the present invention The tsumumo-improving agent of the present invention comprises bile acid and / or a physiologically acceptable salt thereof. Bile acids include cholic acid, deoxycholic acid, ursodeoxycholic acid, lithocholic acid, dehydrocholic acid, lithocholic acid, glycocholic acid, taurocholic acid, tauroglycocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, glycochenodeoxychol Examples thereof include acid, glycodeoxycholic acid, glycolicholic acid, chenodeoxycholic acid, and 7-ketolithocholic acid, and any of these can be used. Examples of physiologically acceptable salts of bile acids include, for example, alkali metal salts such as sodium and potassium, alkaline earth metal salts such as calcium and magnesium, ammonium salts, organic amine salts such as triethylamine and triethanolamine, and lysine. And basic amino acid salts such as arginine and the like. These counterbases may be used alone or in combination of two or more. These bile acids and / or
Alternatively, all physiologically acceptable salts thereof are commercially available and available.
【0011】本発明の胆汁酸及び/又はその生理的に許
容される塩からなる津液改善剤は、津液作用を促進・改
善する効果を有する。津液作用は、その発現形態として
しゃ下作用、利水作用、補陰作用、消導作用として生体
に発現することが知られている。これらの作用を有する
漢方生薬としては、しゃ下作用であれば、ダイオウ、バ
ンシャヨウ、ロカイ、マシニン、ケンゴシ、カンスイ、
ゲンカ、ゾクズイシ、ウキュウコンピ等が知られてお
り、利水作用を有する漢方生薬としては、チョレイ、ブ
クリョウ、タクシャ、インチンコウ、ヨクイニン、トウ
カニン、ジフシ、トウキヒ、キンセンソウ等が知られて
おり、補陰作用を有する漢方生薬としては、シャジン、
セイヨウジン、テンモンドウ、バクモンドウ、セッコ
ク、ギョクチク、ヒャクゴウ、ソウキセイ、カンレンソ
ウ、ジョテイシ、ゴマ、コクズ、キバン、ベッコウ等が
知られており、消導作用を有する漢方生薬としては、サ
ンザシ、クレンコンピ、ヒシ、カクシツ、ライガン、ビ
ンロウジ、ナンカシ、タイサン等が知られている。[0011] The agent for improving a tsunami of the present invention comprising a bile acid and / or a physiologically acceptable salt thereof has an effect of accelerating and improving the activity of a tsuju. It is known that the tsuju action is expressed in a living body as a mode of expression, such as a shampooing action, a water-supplying action, a prosthesis action, and a conduction action. As a herbal medicine having these effects, if it is a shampooing effect, rhubarb, banshayou, rokai, machinin, kengoshi, kansui,
Genka, Zokuzushi, Ryukyu compi and the like are known, and as a Chinese herbal medicine having a water-utilizing effect, Chorei, Bukuryo, Taksha, Inchinko, Yokuinin, Toukanin, Difushi, Toukihi, Kinsenso etc. are known and have a complementing effect. As a herbal medicine, shajin,
Known as Chinese herbal medicines such as Hawthorn, Krenkompi, Hishi and Kakushitsu are known as Chinese herbal medicines having a dissipating effect. , Lygan, Areca, Nankashi, Taisan and the like are known.
【0012】これらについての文献等を調べてみると、
美肌作用、発毛促進作用、抗アレルギー作用、抗炎症作
用、消化促進作用等の薬理作用が重複していることが見
出された。ここに本発明者等は注目し、「水」(津液)
の作用は現代医学における美肌作用、アトピー性皮膚
炎、湿疹、皮膚真菌症、疣贅、色素沈着症、尋常性乾
癬、老人性乾皮症、老人性角化腫、火傷等の皮膚疾患の
治療作用、発毛促進作用、吹き出物の治療作用、消化液
分泌促進作用、発汗促進作用、利尿作用、便通促進作用
等を指標とすることができることを見出した。尚、これ
らの作用の一つを有する物質は、大なり小なり他の作用
も有している場合が多い。したがって、これらの作用の
一つを指標にするスクリーニングを行えば、他の作用の
推定を行うこともできる。Examining the literature etc. about these,
It has been found that pharmacological actions such as beautifying action, hair growth-promoting action, anti-allergic action, anti-inflammatory action, and digestion promoting action overlap. Here, the present inventors pay attention, and consider "water" (Tsu liquid).
Works in modern medicine to treat skin disorders such as skin beautification, atopic dermatitis, eczema, dermatomycosis, warts, pigmentation, psoriasis vulgaris, senile xeroderma, senile keratoma and burns It has been found that the action, the hair growth promoting action, the therapeutic action of pimples, the digestive juice secretion promoting action, the sweat promoting action, the diuretic action, the bowel movement promoting action and the like can be used as indices. In addition, substances having one of these actions often have other actions to a greater or lesser degree. Therefore, if screening is performed using one of these actions as an index, other actions can be estimated.
【0013】本発明の津液改善剤は、美肌作用、アトピ
ー性皮膚炎治療作用、湿疹で代表される皮膚炎群治療作
用、皮膚真菌症治療作用、疣贅治療作用、肝炎で代表さ
れる色素沈着症治療作用、尋常性乾癬治療症、老人性乾
皮症、老人性角化腫治療作用、物理的原因による皮膚損
傷治療作用、発毛促進作用、消化液分泌促進作用、発汗
促進作用、便通促進作用、及び排尿促進(利尿)作用か
らなる群から選ばれる少なくとも一つを改善する作用を
有しており、これを投与することにより、肌の衰えの防
止と改善、アトピー性皮膚炎の治療と発症・悪化の防
止、発毛の促進と抜け毛の予防、湿疹の改善と悪化の予
防、便通の促進と排尿の促進等の効果が発揮される。津
液改善剤の好ましい投与量は、疾病の種類や患者の特性
によって異なるが、成人一人一日あたり、1〜1000
0mgを1回乃至は数回に分けて経口投与すればよい。The essence improving agent of the present invention can be used as a skin beautifying agent, atopic dermatitis treatment, dermatitis group represented by eczema, dermatomycosis treatment, wart treatment, and pigmentation represented by hepatitis. Therapeutic action, psoriasis vulgaris treatment, senile xeroderma, senile keratomas treatment, skin damage treatment due to physical causes, hair growth promotion, digestive juice secretion promotion, sweating promotion, bowel movement promotion It has an effect of improving at least one selected from the group consisting of an action and a urination-promoting (diuretic) action, and by administering it, prevents and ameliorates skin deterioration, and treats atopic dermatitis. Effects such as prevention of onset and deterioration, promotion of hair growth and prevention of hair loss, improvement of eczema and prevention of deterioration, promotion of bowel movement and promotion of urination are exhibited. The preferred dose of the tsukumo ameliorating agent varies depending on the type of disease and the characteristics of the patient, but is preferably 1 to 1000 per adult per day.
0 mg may be orally administered once or divided into several times.
【0014】取り分け本発明で注目すべきことは、胆汁
酸及び/又はその生理的に許容される塩は、経口投与に
よって肌が美しくなったり発毛が促進されたりするな
ど、複数の作用を同時に備えることができる点である。
すなわち、好ましくは、本発明の津液改善剤は、美肌作
用、アトピー性皮膚炎治療作用、湿疹で代表される皮膚
炎群治療作用、皮膚真菌症治療作用、疣贅治療作用、肝
炎で代表される色素沈着症治療作用、尋常性乾癬治療
症、老人性乾皮症、老人性角化腫治療作用、物理的原因
による皮膚損傷治療作用、発毛促進作用、消化液分泌促
進作用、発汗促進作用、便通促進作用、及び利尿作用か
らなる群から選ばれる二以上の作用を改善する効果を有
する。経口投与でこのような作用を同時に期待しうる物
質は未だ知られていない。In particular, it should be noted in the present invention that bile acids and / or physiologically acceptable salts thereof have multiple actions at the same time, for example, by oral administration, the skin becomes beautiful and the hair growth is promoted. The point that can be prepared.
That is, preferably, the essence improving agent of the present invention is represented by a skin beautifying effect, a therapeutic effect on atopic dermatitis, a therapeutic effect on a dermatitis group represented by eczema, a therapeutic effect on dermatomycosis, a therapeutic effect on warts, and a hepatitis. Treatment for pigmentation, treatment for psoriasis vulgaris, treatment for senile xerosis, treatment for senile keratoma, treatment for skin damage due to physical causes, hair growth promotion, digestive secretion promotion, sweating promotion, It has the effect of improving two or more actions selected from the group consisting of a bowel movement promoting action and a diuretic action. There is no known substance capable of simultaneously achieving such an effect by oral administration.
【0015】(2)本発明の経口投与用組成物 本発明の経口投与用組成物は、本発明の上記津液改善剤
を含有することを特徴とする。上記津液改善剤は1種又
は2種以上を含有してもよい。(2) The composition for oral administration of the present invention The composition for oral administration of the present invention is characterized by containing the above-mentioned tsuyu improving agent of the present invention. The above-mentioned Tsutsumi improving agent may contain one kind or two or more kinds.
【0016】経口投与用組成物としては、顆粒剤、散
剤、錠剤、カプセル剤、キャンディー、ガム、グミ等に
加工した食品組成物や医薬組成物が例示できる。好まし
い本発明の津液改善剤の含有量は、食品組成物の場合、
組成物全体に対し0.001〜50重量%であり、0.
01〜20重量%がより好ましく、0.01〜15重量
%が更に好ましい。また、医薬組成物の場合は0.1〜
60重量%が好ましく、0.5〜50重量%がより好ま
しく、1〜30重量%が更に好ましい。Examples of the composition for oral administration include food compositions and pharmaceutical compositions processed into granules, powders, tablets, capsules, candies, gums, gummy gums and the like. The preferred content of the tsukumo improver of the present invention, in the case of a food composition,
0.001 to 50% by weight based on the whole composition;
The content is more preferably from 0.01 to 20% by weight, even more preferably from 0.01 to 15% by weight. Moreover, in the case of a pharmaceutical composition, 0.1 to
It is preferably 60% by weight, more preferably 0.5 to 50% by weight, and still more preferably 1 to 30% by weight.
【0017】本発明の組成物には、上記津液改善剤以外
に、食品組成物、医薬組成物で通常用いられている任意
成分を含有させることができる。このような任意成分と
しては、医薬組成物であれば、賦形剤、結合剤、被覆
剤、滑沢剤、糖衣剤、崩壊剤、増量剤、矯味矯臭剤、乳
化・可溶化・分散剤、安定剤、pH調整剤、等張剤等が
例示でき、食品組成物であれば、酸化防止剤、矯味矯臭
剤、増粘剤、乳化安定剤、防腐剤、呈味剤、甘味剤、酸
味剤等が例示できる。これらの任意成分と上記津液改善
剤を常法に従って処理することにより、本発明の組成物
を製造することができる。[0017] The composition of the present invention may contain, in addition to the above-mentioned tsutsumi-improving agent, optional components commonly used in food compositions and pharmaceutical compositions. As such an optional component, if it is a pharmaceutical composition, an excipient, a binder, a coating agent, a lubricant, a sugar coating, a disintegrant, a bulking agent, a flavoring agent, an emulsifying / solubilizing / dispersing agent, Stabilizers, pH adjusters, isotonic agents, etc. can be exemplified, and in the case of food compositions, antioxidants, flavoring agents, thickeners, emulsion stabilizers, preservatives, flavoring agents, sweeteners, sour agents Etc. can be exemplified. The composition of the present invention can be produced by treating these optional components and the above-mentioned tsukumo improver according to a conventional method.
【0018】本発明の組成物は、津液作用の改善用に用
いることができる。具体的には、美肌作用、アトピー性
皮膚炎治療作用、湿疹で代表される皮膚炎群治療作用、
皮膚真菌症治療作用、疣贅治療作用、肝炎で代表される
色素沈着症治療作用、尋常性乾癬治療症、老人性乾皮
症、老人性角化腫治療作用、物理的原因による皮膚損傷
治療作用、発毛促進作用、消化液分泌促進作用、発汗促
進作用、便通促進作用、及び利尿作用からなる群から選
ばれる作用の改善のために用いることができる。[0018] The composition of the present invention can be used for improving the essence of Tsutsumi. Specifically, beautiful skin action, atopic dermatitis treatment action, dermatitis group treatment action represented by eczema,
Treatment for dermatomycosis, treatment for warts, treatment for pigmentation such as hepatitis, treatment for psoriasis vulgaris, treatment for senile xeroderma, senile keratoma, treatment for skin damage due to physical causes It can be used for improving an action selected from the group consisting of a hair growth promoting action, a digestive juice secretion promoting action, a sweat promoting action, a bowel movement promoting action, and a diuretic action.
【0019】[0019]
【実施例】以下に、本発明の実施例を説明する。Embodiments of the present invention will be described below.
【0020】[0020]
【実施例1〜5】 <配合例>表1に示す処方に従って錠剤を作成した。即
ち、処方成分をグラッド造粒装置に秤込み、50重量部
の20%エタノール水溶液を噴霧しながら混合して、粗
顆粒を作成した。粗顆粒を40℃で48時間送風乾燥し
て、打錠機で打錠して250mgの錠剤を得た。尚、表
1の数値の単位は重量部である。Examples 1 to 5 <Formulation Examples> Tablets were prepared according to the formulations shown in Table 1. That is, the prescription components were weighed into a grading apparatus, and mixed by spraying 50 parts by weight of a 20% aqueous ethanol solution to prepare coarse granules. The coarse granules were blow-dried at 40 ° C. for 48 hours, and were compressed with a tableting machine to obtain 250 mg tablets. The units of the numerical values in Table 1 are parts by weight.
【0021】[0021]
【表1】 [Table 1]
【0022】[0022]
【実施例6〜10】 <配合例>表2に示す成分を用いてその処方に従ってキ
ャンディーを作成した。即ち、処方成分を120℃で加
熱溶解し、冷却しながら成形してキャンディーを得た。
尚、表2中の数値の単位は重量部である。Examples 6 to 10 <Formulation Examples> Using the components shown in Table 2, candy was prepared according to the formulation. That is, the prescription components were heated and melted at 120 ° C. and molded while cooling to obtain a candy.
The units of the numerical values in Table 2 are parts by weight.
【0023】[0023]
【表2】 [Table 2]
【0024】[0024]
【実施例11〜15】 <配合例>表3に示す成分を用いその処方に従ってキャ
ンディーを作成した。即ち、処方成分を120℃で加熱
溶解し、冷却しながら成形してキャンディーを得た。
尚、表3中の数値の単位は重量部である。Examples 11 to 15 <Formulation Examples> Candies were prepared using the components shown in Table 3 according to the formulation. That is, the prescription components were heated and melted at 120 ° C. and molded while cooling to obtain a candy.
The units of the numerical values in Table 3 are parts by weight.
【0025】[0025]
【表3】 [Table 3]
【0026】[0026]
【実施例16】 <試験例1:美肌改善作用>肌荒れに悩む24〜36歳
のパネラー1群10名が、上記実施例1〜3の錠剤(1
g錠)を1日朝晩2回1錠ずつ2ヶ月間のみ、肌荒れの
改善効果を評価した。評価の基準は、非常に改善した
(評点5)〜改善しない(評点0)、とした。対照とし
ては、本発明の津液改善剤を乳糖に置換したものを用い
た。結果を平均評点として表4に示す。これより、本発
明の津液改善剤が内服によって肌荒れを改善する作用を
有すること、即ち、美肌作用を有することがわかる。Example 16 <Test Example 1: Improving Skin Beauty> Ten groups of panelists aged 24-36 years old suffering from rough skin,
g tablets) was evaluated twice a day in the morning and evening twice, one tablet only for two months, to evaluate the effect of improving skin roughness. The evaluation criteria were very improved (gradation 5) to not improved (gradation 0). As a control, lactose was used in place of the liquor improving agent of the present invention. The results are shown in Table 4 as average scores. From this, it can be seen that the rubbing liquid improving agent of the present invention has an effect of improving skin roughness by internal use, that is, has a beautiful skin effect.
【0027】[0027]
【表4】 [Table 4]
【0028】[0028]
【実施例17】 <試験例2:発毛促進作用>C3Hマウス1群5匹の背
部を剃毛し、表5に示す検体10mgを生理食塩水20
0μlに溶解又は分散させ経口投与し、その後の毛の生
え方を観察して発毛促進作用を評価した。対照はベヒク
ルの生理食塩水のみとした。評価の基準は、++(評点
4):対照に比べて著しく早い、+(評点2):対照に
比べて早い、±(評点1):対照に比べてやや早い、−
(評点0):対照に比べて早くない、とした。結果を平
均評点として表5に示す。これより、本発明の津液改善
剤は発毛促進作用に優れることがわかる。Example 17 <Test Example 2: Hair growth promoting action> The back of a group of five C3H mice was shaved, and 10 mg of a sample shown in Table 5 was added to physiological saline 20.
It was dissolved or dispersed in 0 μl and orally administered, and the subsequent hair growth was observed to evaluate the hair growth promoting effect. The control was vehicle saline only. The evaluation criteria are ++ (score 4): significantly earlier than the control, + (score 2): earlier than the control, ± (score 1): slightly earlier than the control, −
(Score 0): Not earlier than control. The results are shown in Table 5 as average scores. From this, it can be seen that the tsukumo improver of the present invention is excellent in hair growth promoting action.
【0029】[0029]
【表5】 [Table 5]
【0030】[0030]
【実施例18】 <試験例3:アトピー性皮膚炎に対する作用>アトピー
性皮膚炎に悩む21〜39歳のパネラー1群10名が、
上記実施例1〜3の錠剤(1g錠)を1日朝晩2回1錠
ずつ2ヶ月間のみ、アトピー性皮膚炎の改善効果を評価
した。評価の基準は、非常に改善した(評点5)〜改善
しない(評点0)、とした。対照としては、本発明の津
液改善剤を乳糖に置換したものを用いた。結果を平均評
点として表6に示す。これより、本発明の津液改善剤が
内服によってアトピー性皮膚炎を改善する作用を有する
ことがわかる。Example 18 <Test Example 3: Effect on atopic dermatitis> Ten groups of panelists aged 21 to 39 years old suffering from atopic dermatitis
The improvement effect of atopic dermatitis was evaluated only for the tablets (1 g tablets) of the above Examples 1 to 3 twice a day for 2 months. The evaluation criteria were very improved (gradation 5) to not improved (gradation 0). As a control, lactose was used in place of the liquor improving agent of the present invention. The results are shown in Table 6 as average scores. From this, it can be seen that the tsumugi improver of the present invention has an effect of improving atopic dermatitis by taking it internally.
【0031】[0031]
【表6】 [Table 6]
【0032】[0032]
【実施例19】 <試験例4:湿疹治療作用>湿疹に悩む19〜29歳の
パネラー1群10名が、上記実施例1〜3の錠剤(1g
錠)を1日朝晩2回1錠ずつ2ヶ月間のみ、湿疹の改善
効果を評価した。評価の基準は、非常に改善した(評点
5)〜改善しない(評点0)、とした。対照としては、
本発明の津液改善剤を乳糖に置換したものを用いた。結
果を平均評点として表7に示す。これより、本発明の津
液改善剤が内服によって湿疹を改善する作用を有するこ
とがわかる。Example 19 <Test Example 4: Eczema Treatment> Ten groups of panelists aged 19 to 29 years old suffering from eczema were given the tablets (1 g) of Examples 1 to 3 above.
Tablets) was evaluated twice a day, in the morning and evening, one tablet at a time for 2 months only, to evaluate the effect of improving eczema. The evaluation criteria were very improved (gradation 5) to not improved (gradation 0). As a control,
A liquor of the present invention in which lactose was substituted was used. The results are shown in Table 7 as average scores. From this, it can be seen that the tsukutsu improver of the present invention has an effect of improving eczema by taking it internally.
【0033】[0033]
【表7】 [Table 7]
【0034】[0034]
【実施例20】 <試験例5:胃液分泌促進作用>麻酔犬を用いて胃液の
分泌促進を見た。即ち、ペントバルビツールで麻酔した
犬の胃に投与装置付き内視鏡を導入し、検体として表8
に示す本発明の津液改善剤10mgを生理食塩水10m
lに溶解又は分散させて投与し、その前後の胃液の分泌
を観察して胃液分泌促進作用を評価した。対照は生理食
塩水のみを用いた。評価の基準は、++(評点4):対
照に比べて著しく胃液分泌が増大、+(評点2):対照
に比べて胃液分泌が増大、±(評点1):対照に比べて
やや分泌が増大、−(評点0):分泌が対照に比べて増
大せず、とした。結果を表8に示す。これより、本発明
の津液改善剤は胃液分泌促進作用に優れることがわか
る。Example 20 <Test Example 5: Gastric secretion promoting effect> The secretion of gastric juice was examined using an anesthetized dog. That is, an endoscope with an administration device was introduced into the stomach of a dog anesthetized with a pentobarbitur, and the sample was treated as shown in Table 8.
10 mg of the tsukumo improver of the present invention shown in
The solution was administered by dissolving or dispersing the solution in the gastric acid, and the secretion of gastric juice before and after the administration was observed to evaluate the gastric secretion promoting action. As a control, only physiological saline was used. Evaluation criteria were as follows: ++ (score 4): gastric secretion increased significantly compared to control, + (score 2): increased gastric secretion compared to control, ± (score 1): slightly increased compared to control ,-(Score 0): the secretion did not increase compared to the control. Table 8 shows the results. From this, it can be seen that the tsumugi improving agent of the present invention is excellent in gastric secretion promoting action.
【0035】[0035]
【表8】 [Table 8]
【0036】[0036]
【実施例21】 <試験例6:便通・排尿の促進作用>ICRマウスを代
謝ケージで飼育した。投与群は実施例1〜3の組成物を
1g/1日/1匹毎日朝夕2回0.5gずつ経口投与し
た。24時間尿と糞の量をモニターした。コントロール
群は検体を投与しなかった。各サンプル1群10匹とし
た。検体投与群の尿量の総和をコントロール群の尿量の
総和で除した値と検体投与群の糞量の総和をコントロー
ル群の糞量の総和で除した値とを表9に示す。これよ
り、本発明の胆汁酸及び/又はその生理的に許容される
塩は便通促進作用及び排尿促進作用(利尿作用)に優れ
ることがわかる。Example 21 <Test Example 6: Promotion of bowel movement and urination> ICR mice were bred in metabolic cages. In the administration group, the compositions of Examples 1 to 3 were orally administered at a dose of 0.5 g twice daily in the morning and evening at 1 g / day / animal. Urine and fecal volume were monitored for 24 hours. The control group received no specimen. Each group consisted of 10 animals. Table 9 shows the value obtained by dividing the total urine volume of the sample administration group by the total urine volume of the control group and the value obtained by dividing the total fecal volume of the sample administration group by the total fecal volume of the control group. This indicates that the bile acid and / or a physiologically acceptable salt thereof of the present invention is excellent in a bowel movement promoting action and a urination promoting action (diuretic action).
【0037】[0037]
【表9】 [Table 9]
【0038】[0038]
【発明の効果】本発明によれば、美肌作用、アトピー性
皮膚炎治療作用、湿疹で代表される皮膚炎群治療作用、
皮膚真菌症治療作用、疣贅治療作用、肝炎で代表される
色素沈着症治療作用、尋常性乾癬治療症、老人性乾皮
症、老人性角化腫治療作用、物理的原因による皮膚損傷
治療作用、発毛促進作用、消化液分泌促進作用、発汗促
進作用、便通促進作用、及び利尿作用からなる群から選
ばれる津液作用を改善する効果を有する津液改善剤を提
供することができる。According to the present invention, a beautiful skin effect, a therapeutic effect on atopic dermatitis, a therapeutic effect on a dermatitis group represented by eczema,
Treatment for dermatomycosis, treatment for warts, treatment for pigmentation such as hepatitis, treatment for psoriasis vulgaris, treatment for senile xeroderma, senile keratoma, treatment for skin damage due to physical causes The present invention can provide a tsumucolytic agent having an effect of improving a tsukusei effect selected from the group consisting of a hair growth promoting action, a digestive juice secretion promoting action, a sweating promoting action, a bowel movement promoting action, and a diuretic action.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 FI A61K 31/575 ACX A61K 31/575 ACX ADA ADA ADZ ADZ (72)発明者 福島 信 神奈川県横浜市戸塚区柏尾町560 ポーラ 化成工業株式会社戸塚研究所内 (72)発明者 稲岡 靖規 神奈川県横浜市神奈川区高島台27番地1 ポーラ化成工業株式会社横浜研究所内 (72)発明者 奥田 剛弘 神奈川県横浜市神奈川区高島台27番地1 ポーラ化成工業株式会社横浜研究所内────────────────────────────────────────────────── ─── Continued on the front page (51) Int.Cl. 6 Identification code FI A61K 31/575 ACX A61K 31/575 ACX ADA ADA ADZ ADZ (72) Inventor Shin Fukushima 560 Kashiocho Kashio-cho, Totsuka-ku, Yokohama-shi, Kanagawa-ken Inside the Totsuka Research Laboratory, Inc. Polar Chemical Industry Co., Ltd. Yokohama Research Laboratory
Claims (7)
る塩からなる、津液改善剤。1. An agent for improving tsunami comprising a bile acid and / or a physiologically acceptable salt thereof.
記載の津液改善剤。2. The method of claim 1, wherein said bile acid is cholic acid.
The rubbing improver according to the above.
する、経口投与用組成物。3. A composition for oral administration, comprising the tsukumo ameliorating agent according to claim 1 or 2.
〜5のいずれかに記載の組成物。6. The method according to claim 3, which is used for improving a tsufluid action.
The composition according to any one of claims 1 to 5.
皮膚炎治療作用、皮膚炎群治療作用、皮膚真菌症治療作
用、疣贅治療作用、色素沈着症治療作用、尋常性乾癬治
療症、老人性乾皮症、老人性角化腫治療作用、皮膚損傷
治療作用、発毛促進作用、消化液分泌促進作用、発汗促
進作用、便通促進作用、及び利尿作用からなる群から選
ばれる作用である、請求項6記載の組成物。7. The tanning solution is effective for beautifying skin, treating atopic dermatitis, treating dermatitis, treating dermatomycosis, treating warts, treating pigmentation, treating psoriasis vulgaris, and the elderly. Xeroderma sclerosis, senile keratoma treatment action, skin damage treatment action, hair growth promotion action, digestive secretion promotion action, perspiration promotion action, bowel movement promotion action, and an action selected from the group consisting of diuretic action, A composition according to claim 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8272724A JPH10114665A (en) | 1996-10-15 | 1996-10-15 | Improver for aqueous body fluid and composition for oral administration comprising the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8272724A JPH10114665A (en) | 1996-10-15 | 1996-10-15 | Improver for aqueous body fluid and composition for oral administration comprising the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH10114665A true JPH10114665A (en) | 1998-05-06 |
Family
ID=17517903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP8272724A Pending JPH10114665A (en) | 1996-10-15 | 1996-10-15 | Improver for aqueous body fluid and composition for oral administration comprising the same |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH10114665A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002205998A (en) * | 2000-10-20 | 2002-07-23 | Daicho Kikaku:Kk | Nutrition and digestive products |
| JP2004182600A (en) * | 2001-10-31 | 2004-07-02 | Daicho Kikaku:Kk | Skin preparation |
| US7678782B2 (en) * | 2000-10-06 | 2010-03-16 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
| JP2012193200A (en) * | 2001-10-31 | 2012-10-11 | Daicho Kikaku:Kk | Dermatologic preparation |
| JP2014162761A (en) * | 2013-02-26 | 2014-09-08 | Kao Corp | BLOOD apoCI CONCENTRATION REDUCER |
| JP2016505616A (en) * | 2013-08-26 | 2016-02-25 | ソウル テクノ ホールディングス、インク.Seoul Techno Holdings, Inc. | Composition for prevention or treatment of allergic skin disease containing GPCR19 agonist as active ingredient {Composition for preventing or allergic dermatitis compounding GPCR 19 agonistasactive ingredient} |
| JP2019127471A (en) * | 2018-01-26 | 2019-08-01 | 株式会社ヤマザキ | Composition for beautiful skin |
| JP2024531781A (en) * | 2021-09-15 | 2024-08-29 | シャペロン インク. | Gel composition for preventing or treating atopic dermatitis |
-
1996
- 1996-10-15 JP JP8272724A patent/JPH10114665A/en active Pending
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7678782B2 (en) * | 2000-10-06 | 2010-03-16 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
| JP2002205998A (en) * | 2000-10-20 | 2002-07-23 | Daicho Kikaku:Kk | Nutrition and digestive products |
| JP2004182600A (en) * | 2001-10-31 | 2004-07-02 | Daicho Kikaku:Kk | Skin preparation |
| JP2012193200A (en) * | 2001-10-31 | 2012-10-11 | Daicho Kikaku:Kk | Dermatologic preparation |
| JP2014208697A (en) * | 2001-10-31 | 2014-11-06 | 有限会社大長企画 | Agent for the skin of animals |
| JP2014162761A (en) * | 2013-02-26 | 2014-09-08 | Kao Corp | BLOOD apoCI CONCENTRATION REDUCER |
| JP2016505616A (en) * | 2013-08-26 | 2016-02-25 | ソウル テクノ ホールディングス、インク.Seoul Techno Holdings, Inc. | Composition for prevention or treatment of allergic skin disease containing GPCR19 agonist as active ingredient {Composition for preventing or allergic dermatitis compounding GPCR 19 agonistasactive ingredient} |
| JP2017114879A (en) * | 2013-08-26 | 2017-06-29 | ソウル テクノ ホールディングス、インク.Seoul Techno Holdings, Inc. | Composition for preventing or treating allergic dermatitis comprising gpcr19 agonist as an active ingredient |
| JP2019112405A (en) * | 2013-08-26 | 2019-07-11 | シャペロン インク. | Composition for preventing or treating allergic dermatitis comprising gpcr19 agonist as an active ingredient |
| JP2019127471A (en) * | 2018-01-26 | 2019-08-01 | 株式会社ヤマザキ | Composition for beautiful skin |
| JP2024531781A (en) * | 2021-09-15 | 2024-08-29 | シャペロン インク. | Gel composition for preventing or treating atopic dermatitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH10114649A (en) | Improver for aqueous body fluid and composition for oral administration comprising the same | |
| JP2001064192A (en) | Migration inhibitor for langerhans cell and antigen presentation inhibitor | |
| JP2000103718A (en) | Composition for improving activity of living body | |
| WO1994001099A1 (en) | Pharmaceutical composition having anti-alcohol, radioprotecting and anti-choleraic activity and stimulating energy metabolism, stomach mucous membrane acid-generation and secretion functions | |
| JP7706025B2 (en) | Preparation for treating and/or preventing polycystic ovary syndrome and method for producing same | |
| JPH05505819A (en) | Compositions and methods for treating acne vulgaris and delaying aging | |
| JP2003088329A (en) | Analgesic health supplement | |
| JPH10120579A (en) | Skin preparation for improving sputum for external use | |
| RU2114630C1 (en) | Antidiabetic agent "samsar" | |
| JPH0344324A (en) | Sexual function invigorator | |
| CN113398237B (en) | A kind of traditional Chinese medicine composition for antibacterial, antipruritic and antidandruff and preparation method thereof | |
| JPH10175859A (en) | External preparation for skin for improving water (of chinese medicine idea) | |
| JP4049406B2 (en) | Tsu fluid improving agent and composition for oral administration containing the same | |
| JP4018764B2 (en) | Skin preparation for improving tsunami | |
| JPH10120558A (en) | Skin preparation for improving sputum for external use | |
| JPH10114652A (en) | Improver for aqueous body fluid and composition for oral administration comprising the same | |
| JPH10175852A (en) | Water (of chinese medicine idea) improver and composition for oral administration containing the same | |
| CN110623993A (en) | Compound nutritional tablet of traditional Chinese medicine composition for treating gynecological inflammation and preparation method thereof | |
| JPH10120561A (en) | Skin preparation for improving sputum for external use | |
| US20060275505A1 (en) | Method and composition for increasing the alkalinity of the body | |
| JPH10175860A (en) | Water (of chinese medicine idea) improver and composition for oral administration containing the same | |
| JPH0761953B2 (en) | Manufacturing method of immunity strengthening and constitution improving agent | |
| JPH10123117A (en) | Method for judging secretion funetion | |
| JPH08133983A (en) | Extract of aspalathus linealis and its use | |
| Sutherland | THE SYDNEY FUNNEL–WEB SPIDER (ATRAX ROBUSTUS): 1: A REVIEW OF PUBLISHED STUDIES ON THE CRUDE VENOM |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070612 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071016 |